lorcaserin hydrochloride XR + Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Obesity
Conditions
Obesity
Trial Timeline
Sep 28, 2017 → Apr 3, 2020
NCT ID
NCT03338296About lorcaserin hydrochloride XR + Placebo
lorcaserin hydrochloride XR + Placebo is a approved stage product being developed by Eisai for Obesity. The current trial status is terminated. This product is registered under clinical trial identifier NCT03338296. Target conditions include Obesity.
What happened to similar drugs?
20 of 20 similar drugs in Obesity were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03338296 | Approved | Terminated |
Competing Products
20 competing products in Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 35 |
| MK0557 | Merck | Phase 3 | 40 |
| AMG 786 | Amgen | Phase 1 | 29 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 39 |
| Tirzepatide | Eli Lilly | Phase 2 | 42 |
| exenatide + Placebo | Eli Lilly | Approved | 43 |
| Brenipatide | Eli Lilly | Phase 1 | 36 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 47 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 32 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 30 |
| PG-102 | Rani Therapeutics | Phase 1 | 26 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 40 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 29 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 27 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 29 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 29 |
| Tirzepatide | Eli Lilly | Approved | 50 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 26 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 43 |